LONDON (AP) – Manufacturers of drugs Sanofi and GlaxoSmithKline say they will seek regulatory approval for a new vaccine against COVID-19 after human trials have shown that it provides a high level of protection against the disease.

A statement from the companies said that late-stage trials found that two doses of the vaccine were about 58% effective in preventing infection and 75% effective in preventing moderate to severe disease.

They said a separate study using the vaccine as a booster showed that it “caused a significant increase in neutralizing antibodies.”

Roger Connor, president of GSK Vaccines, says “the evolving epidemiology of COVID-19 demonstrates the need for a variety of vaccines.”

“Our candidate for a protein-based adjuvant vaccine uses a well-established approach that is widely used to prevent infection with other viruses, including pandemic influenza,” he said. “We are confident that this vaccine can play an important role as we continue to fight this pandemic and prepare for the post-pandemic period.”

Novavax is also seeking approval for its protein-based COVID-19 vaccine.

The two-dose mRNA vaccines Moderna and Pfizer are currently approved by the Food and Drug Administration. The Johnson and Johnson single-dose vaccine operates under an emergency use permit.

Source link